IL33 and neoplasm: The interplay between IL-31, IL-33, eosinophils, and the tumor microenvironment (TME) could significantly influence immunotherapy outcomes in NSCLC, and understanding these mechanisms is crucial for enhancing therapeutic efficacy and overcoming treatment resistance.